Tigress Financial Cuts Medline (NASDAQ:MDLN) Price Target to $55.00

Medline (NASDAQ:MDLN) had its price objective lowered by Tigress Financial from $62.00 to $55.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts also recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $47.00 price objective on shares of Medline in a research report on Thursday, August 6th. Sanford C. Bernstein reduced their target price on shares of Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Citigroup upgraded shares of Medline to a “strong-buy” rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft set a $37.00 price target on Medline in a report on Thursday, August 6th. Finally, Stifel Nicolaus dropped their price target on Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.42.

Medline Stock Performance

Shares of MDLN opened at $35.58 on Tuesday. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. The firm has a market cap of $46.74 billion and a PE ratio of 111.19. The company’s 50 day simple moving average is $38.26 and its 200-day simple moving average is $41.43. Medline has a 12-month low of $32.81 and a 12-month high of $50.88.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. As a group, equities analysts predict that Medline will post 1.49 EPS for the current year.

Insider Activity at Medline

In other news, insider Jessi L. Corcoran acquired 5,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the purchase, the insider owned 5,000 shares of the company’s stock, valued at $170,750. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Private Ltd Gic sold 1,976,618 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $35.60, for a total transaction of $70,367,600.80. Following the transaction, the insider owned 25,264,760 shares of the company’s stock, valued at approximately $899,425,456. The trade was a 7.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,938,896 shares of company stock worth $104,656,454 in the last three months. Insiders own 0.81% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MDLN. Bank of New York Mellon Corp acquired a new stake in Medline in the second quarter valued at about $40,430,000. E. Ohman J or Asset Management AB acquired a new position in Medline during the 2nd quarter worth approximately $508,000. GAMMA Investing LLC increased its position in Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after purchasing an additional 254 shares during the period. Parallel Advisors LLC raised its stake in shares of Medline by 1,073.3% during the 1st quarter. Parallel Advisors LLC now owns 5,280 shares of the company’s stock worth $235,000 after buying an additional 4,830 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new position in shares of Medline during the 1st quarter worth approximately $1,048,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline’s second-quarter results were a key support for the stock: earnings of $0.50 per share exceeded the $0.32 consensus estimate, while revenue reached approximately $7.7 billion. The earnings call provided investors with additional management commentary on the company’s outlook. Medline Q2 2026 earnings call transcript
• Positive Sentiment: JPMorgan lowered its price target to $46 but retained an Overweight rating, while TD Cowen and Tigress Financial maintained positive ratings with targets of $45 and $55, respectively. These targets imply meaningful upside and suggest some analysts view the recent weakness as excessive.
• Neutral Sentiment: Despite multiple target reductions, analyst sentiment remains broadly favorable. Medline has a consensus rating of “Moderate Buy,” although the average target has fallen to about $47.69, indicating that expectations are being recalibrated.
• Negative Sentiment: Medline convenience kits are affected by recalled Becton Dickinson applicators linked to sterility and contamination risks. The FDA alert and Medline’s corrective actions could create operational, regulatory and reputational concerns, although the report does not indicate the full financial impact. FDA alert on Medline convenience kits
• Negative Sentiment: Kaplan Fox and Kessler Topaz Meltzer & Check announced investigations into potential securities-law violations. The announcements do not establish wrongdoing, but they add legal uncertainty and may weigh on investor confidence. Kessler Topaz Medline investigation
• Negative Sentiment: Wells Fargo cut its price target to $34 and assigned an Equal Weight rating, signaling limited near-term upside. Major shareholder GIC also sold additional Medline shares, including 590,284 shares in the latest disclosed transaction, reducing its position by 2.36%.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.